Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Pembro + CRT in HNSCC fails to deliver statistically significant event-free...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

Lenvatinib remains standard of care for first-line therapy in advanced...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

New era of early cancer detection blood tests on the horizon

Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA

New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )

Hyperthermic intraperitoneal chemo for locally advanced colon cancer

Dr Álvaro Arjona-Sánchez- Reina Sofia University Hospital, Cordoba, Spain

Hyperthermic intraperitoneal chemo for locally advanced colon cancer ( Dr Álvaro Arjona-Sánchez- Reina Sofia University Hospital, Cordoba, Spain )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine...

Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht...

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy ( Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands )

Prognostic model of all-cause mortality at 30 days in patients with cancer and...

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )

New data presented at ESMO for multi-cancer early detection

Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences

New data presented at ESMO for multi-cancer early detection ( Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences )

Perioperative nivolumab did not improve RFS in RCC patients at high risk for...

Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence ( Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA )

More from ecancer